Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV for mucosal healing in moderately to severely active Crohn's disease
2014-003509-13Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vedolizumab in Crohn's disease, sponsored by Takeda. Primary endpoint: Endoscopic remission at Week 26. Started Apr 2015; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-003509-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003509-13.